These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15998635)

  • 21. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription.
    Lee D; Kim JW; Seo T; Hwang SG; Choi EJ; Choe J
    J Biol Chem; 2002 Jun; 277(25):22330-7. PubMed ID: 11950834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    Zache N; Lambert JM; Wiman KG; Bykov VJ
    Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.
    Issaeva N; Friedler A; Bozko P; Wiman KG; Fersht AR; Selivanova G
    Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13303-7. PubMed ID: 14595027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity.
    Mueller A; Schäfer BW; Ferrari S; Weibel M; Makek M; Höchli M; Heizmann CW
    J Biol Chem; 2005 Aug; 280(32):29186-93. PubMed ID: 15941720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.
    He XX; Zhang YN; Yan JW; Yan JJ; Wu Q; Song YH
    Tumour Biol; 2016 Jan; 37(1):807-15. PubMed ID: 26250460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
    Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
    Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding.
    Zaman S; Yu X; Bencivenga AF; Blanden AR; Liu Y; Withers T; Na B; Blayney AJ; Gilleran J; Boothman DA; Loh SN; Kimball SD; Carpizo DR
    Mol Cancer Ther; 2019 Aug; 18(8):1355-1365. PubMed ID: 31196889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
    Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ
    Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
    Farnebo M; Bykov VJ; Wiman KG
    Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Thiol Reactivity for Targeting Mutant p53.
    Zhang Q; Bergman J; Wiman KG; Bykov VJN
    Cell Chem Biol; 2018 Oct; 25(10):1219-1230.e3. PubMed ID: 30057300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.
    Madan E; Parker TM; Bauer MR; Dhiman A; Pelham CJ; Nagane M; Kuppusamy ML; Holmes M; Holmes TR; Shaik K; Shee K; Kiparoidze S; Smith SD; Park YA; Gomm JJ; Jones LJ; Tomás AR; Cunha AC; Selvendiran K; Hansen LA; Fersht AR; Hideg K; Gogna R; Kuppusamy P
    J Biol Chem; 2018 Mar; 293(12):4262-4276. PubMed ID: 29382728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
    Liang Y; Besch-Williford C; Hyder SM
    Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P53: an ubiquitous target of anticancer drugs.
    Blagosklonny MV
    Int J Cancer; 2002 Mar; 98(2):161-6. PubMed ID: 11857402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant p53 rescue and modulation of p53 redox state.
    Bykov VJ; Lambert JM; Hainaut P; Wiman KG
    Cell Cycle; 2009 Aug; 8(16):2509-17. PubMed ID: 19633417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells.
    Karimi M; Conserva F; Mahmoudi S; Bergman J; Wiman KG; Bykov VJ
    Carcinogenesis; 2010 Jun; 31(6):1045-53. PubMed ID: 20427345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis.
    Shi Y; Sahu RP; Srivastava SK
    BMC Cancer; 2008 Oct; 8():294. PubMed ID: 18847491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
    Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
    Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.